Info

The Immune Response Corporation was co-founded in 1986 by Dr. Jonas Salk, discoverer of the polio vaccine, as a biopharmaceutical company dedicated to treating human immunodeficiency virus (HIV). The Company's lead product candidate, REMUNE®, is an immune-based therapy (IBT) designed by Dr. Salk to induce a specific immune response in individuals already infected by HIV and boost the body's natural defense mechanisms in order to slow HIV disease progression. REMUNE® has been studied in over 2,000 patients and has been shown to be well tolerated. Data from these studies suggest that REMUNE® may have activity in promoting the immune system's own ability to defend against HIV when used alone or in conjunction with antiretroviral drugs. REMUNE® is currently in Phase II clinical development. A new HIV immune-based therapy, IR103, which incorporates a second-generation immunostimulatory oligonucleotide adjuvant, is currently in Phase I/II clinical trials in Canada and the United Kingdom. The Company is also developing an IBT for multiple sclerosis (MS), NeuroVax, which is currently in Phase II and has shown potential therapeutic value for this difficult to treat disease.